Join the club for FREE to access the whole archive and other member benefits.

Owlstone Medical raised $58M to advance its breath biopsy technology

Developing painless tests to detect lung cancer, liver diseases, respiratory diseases, and gut health


Key points from article :

Owlstone Medical raised $58 million to support its efforts in the field of breath biopsy.

Series D funding brings the total venture capital haul to over $150 million.

Funds to accelerate projects focused on lung cancer, liver diseases and respiratory conditions.

Other offerings under development include measures of gut function and food intolerance.

Its first commercial breath biopsy panel, launched this January, distinguishes various chronic inflammatory airway conditions.

A clinical study showed Owlstone’s devices could work as noninvasive diagnostic tests for nonalcoholic liver diseases.

It did so by not just passively collecting breaths but by giving the body something to chew on and seeing how it responds.

Using food additive as a chemical probe, limonene, Owlstone found that people with liver cancer or cirrhosis were unable to sufficiently metabolize and clear out the compound.

Probe-based approach could also be applied to areas such as lung cancer, said Owlstone co-founder and CEO Billy Boyle.

Mentioned in this article:

Click on resource name for more details.

Billy Boyle

Co-Founder and CEO at Owlstone Medical Ltd.

Owlstone Medical

Company focused to development of non-invasive diagnostics for cancer and inflammatory diseases.

Topics mentioned on this page:
Investments, Diagnostics